GlassScriptPhysician profile
Troy A Gatcliffe
NPI 1396713889
$171,507.78
in general payments reported to CMS, 2019-2025
14 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,962 · 2020: $12K · 2021: $48K · 2022: $93K · 2023: $15K · 2024: $135 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $12K · Food and Beverage: $1,963 · Travel and Lodging: $1,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $12,000.00 |
| Food and Beverage | $1,963.03 |
| Travel and Lodging | $1,743.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $139,213.43 | 2019-2023 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $28,590.49 | 2019-2025 | Jemperli, Zejula |
| Tesaro, INC. | $1,417.47 | 2019 | |
| Conmed Corporation | $702.36 | 2019-2023 | Airseal |
| Abbvie INC. | $563.18 | 2020-2025 | |
| Ethicon US, LLC | $253.49 | 2021-2023 | Vistaseal, Stratafix, Echelon Circular |
| Bard Peripheral Vascular, INC. | $183.25 | 2022 | |
| Myriad Genetic Laboratories, INC. | $159.58 | 2021-2024 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $107.71 | 2019 | |
| Covidien LP | $100.00 | 2019 | |
| Seagen INC. | $65.38 | 2022 | |
| Eisai INC. | $63.77 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $53.80 | 2022-2025 | Lynparza, Keytruda |
| Medtronic, INC. | $33.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Gatcliffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.